Aridis Pharmaceuticals (ARDS) Given a $25.00 Price Target at Maxim Group

Maxim Group set a $25.00 target price on Aridis Pharmaceuticals (NASDAQ:ARDS) in a research note issued to investors on Thursday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently commented on the stock. Northland Securities reaffirmed a buy rating and issued a $40.00 target price on shares of Aridis Pharmaceuticals in a research report on Wednesday, April 17th. Zacks Investment Research raised shares of Aridis Pharmaceuticals from a hold rating to a buy rating and set a $12.00 target price for the company in a research report on Tuesday, April 2nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Aridis Pharmaceuticals has a consensus rating of Buy and a consensus price target of $27.50.

NASDAQ:ARDS opened at $9.40 on Thursday. Aridis Pharmaceuticals has a 12 month low of $7.59 and a 12 month high of $13.85. The stock has a market capitalization of $76.21 million and a PE ratio of -1.34.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.12). Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%. The company had revenue of $1.02 million during the quarter. As a group, research analysts predict that Aridis Pharmaceuticals will post -2.52 earnings per share for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Read More: Buy-Side Analysts

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.